Výsledky vyhledávání - "M. A. Maurer"

Monitoring for arrhythmia in transthyretin cardiac amyloidosis with remote patch devices

Autor: S Bruce, M Cuomo, H Yarmohammadi, E Y Wan, D Saluja, R Sciacca, H Garan, J M Griffin, M S Maurer, A B Biviano

Publikováno v: Europace. 25

Funding Acknowledgements Type of funding sources: None. Background/Introduction Transthyretin cardiac amyloidosis (ATTR-CA) is associated with an increased incidence of arrhythmias. We hypothesized that non-invasive, two-week outpatient cardiac rhyth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e7ad396f62775fc639360a16903c4bd2
https://doi.org/10.1093/europace/euad122.631

Zobrazit plný text záznamu

NNC6019–0001, a humanized monoclonal antibody, in patients with transthyretin amyloid cardiomyopathy (ATTR-CM): rationale and study design of a phase 2, randomized, placebo-controlled trial

Autor: M Fontana, K Buchholtz, M D M Engelmann, M Grogan, G K Hovingh, A V Kristen, P Poulsen, S J Shah, M S Maurer

Publikováno v: European Heart Journal. 43

Introduction Transthyretin amyloid cardiomyopathy (ATTR-CM) is a chronic condition associated with progressive heart failure, resulting from extracellular deposition of misfolded transthyretin (TTR) protein as amyloid fibrils in the myocardium. Curre

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::159fa4765d5def53fd337b15e68ca433
https://doi.org/10.1093/eurheartj/ehac544.1767

Zobrazit plný text záznamu

Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using proteomics profiling

Autor: N Harano, L W Liang, K Hasegawa, M S Maurer, A Tower-Rader, M A Fifer, M P Reilly, Y J Shimada

Publikováno v: European Heart Journal. 43

Background Hypertrophic cardiomyopathy (HCM) is one of the most common genetic cardiac disorders and affects 1 in 200–500 individuals. HCM is known to be heterogeneous. Approximately 20–30% of patients with HCM develop atrial fibrillation (AF), w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6bce3bcf366711d92f2d44d00aaa56d1
https://doi.org/10.1093/eurheartj/ehac544.1727

Zobrazit plný text záznamu

Proteomics profiling reveals signaling pathways associated with major adverse cardiovascular events in patients with hypertrophic cardiomyopathy

Autor: C Lee, L W Liang, K Hasegawa, M S Maurer, A Tower-Rader, M A Fifer, M P Reilly, Y J Shimada

Publikováno v: European Heart Journal. 43

Background Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy affecting 1 in 200–500 people in the US. It is characterized by a diverse clinical course, and only a subset of patients with HCM experience major adverse cardio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c2464603a5d71f7eec37d2c67a679306
https://doi.org/10.1093/eurheartj/ehac544.1724

Zobrazit plný text záznamu

Quantum dot coupled to topological insulators: The role of edge states

Autor: M. T. Maurer, Y.-T. Lin, D. M. Kennes, M. Pletyukhov, H. Schoeller, V. Meden

Publikováno v: Physical Review B

We investigate a system consisting of one or two topological-insulator leads which are tunnel coupled to a single dot level. The leads are described by the one-dimensional Su-Schrieffer-Heeger model. We show that (topological) edge states cause chara

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87eb58641b677084b751bc70e255248e
https://hdl.handle.net/21.11116/0000-000A-922D-F21.11116/0000-000A-922F-D

Zobrazit plný text záznamu

Proteomics profiling reveals distinct molecular subtypes of hypertrophic cardiomyopathy with differential risks of major adverse cardiovascular events

Autor: L W Liang, Y Raita, K Hasegawa, M A Fifer, M S Maurer, M P Reilly, Y J Shimada

Publikováno v: European Heart Journal. 42

Background Hypertrophic cardiomyopathy (HCM) is a heterogeneous disease, and a subset (10–15%) of patients per year experience major adverse cardiovascular events (MACE). Current risk prediction models based solely on clinical data have yielded lim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6cc1490feff3983f8d86d2c7895bde21
https://doi.org/10.1093/eurheartj/ehab724.1765

Zobrazit plný text záznamu

Comprehensive proteomics profiling identifies patients with late gadolinium enhancement on cardiac magnetic resonance imaging in the hypertrophic cardiomyopathy population

Autor: B S Lander, Y Zhao, K Hasegawa, M S Maurer, M A Fifer, M P Reilly, Y J Shimada

Publikováno v: European Heart Journal. 42

Introduction Late gadolinium enhancement (LGE) on cardiac magnetic resonance imaging (CMR) represents myocardial fibrosis. In patients with hypertrophic cardiomyopathy (HCM), LGE on CMR has been associated with an increased risk of sudden cardiac dea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eecb22a0f1a3d8ab511d35bb77d21d6d
https://doi.org/10.1093/eurheartj/ehab724.1764

Zobrazit plný text záznamu

Comprehensive proteomics profiling reveals molecular pathways that are differentially regulated in hypertrophic cardiomyopathy and correlate with clinical markers of disease severity

Autor: Y J Shimada, Y Raita, L W Liang, M S Maurer, K Hasegawa, M A Fifer, M P Reilly

Publikováno v: European Heart Journal. 42

Background Hypertrophic cardiomyopathy (HCM) is caused by mutations in the genes coding for proteins essential in normal myocardial contraction. However, it remains unclear through which molecular pathways gene mutations mediate the development and p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e6f4c8313545ff8a09207573b6aa6d8d
https://doi.org/10.1093/eurheartj/ehab724.1777

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání